Contents

Volume 91 Issue 6 | JNNP June 2020

2020 Vision
563 What contributes to quality of life in Parkinson’s disease: a re-evaluation
A Schrag, N Quinn

566 Too much of a good thing: hedonistic homoeostatic dysregulation and other behavioural consequences of excessive dopamine replacement therapy in Parkinson’s disease
J D O’Sullivan

Editorial comments
568 Neurology in the time of COVID-19
H Manji, A S Carr, W J Brownlee, M P Lunn

571 Remember the null hypothesis?
C Randolph

Autonomic
572 New insights in post-traumatic headache with cluster headache phenotype: a cohort study
L Gramgeon, E O’Connor, C-K Chau, L Abijain, T M Pham Ngoc, M S Matharu

Cerebrovascular disease
580 Ten-year risks of recurrent stroke, disability, dementia and cost in relation to site of primary intracerebral haemorrhage: population-based study
L Li, R Luengo-Fernandez, S M Zauscher, N C Reddows, P Lavallée, L E Silver, W Kuker, P M Rothwell

Cognitive neurology
586 Clinical and neuropsychological profile of patients with dementia and chronic traumatic encephalopathy
C LoBue, J Schaffer, C M Callum, M E Peters, N Didehbani, J Hart, C L White

Migraine
593 Migraine and risk of stroke
L R Ote, T Kurth, S Gallat, D W Dodick

Neuro-inflammation
605 CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD

Neurodegeneration
612 Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia

2020 Vision
563 What contributes to quality of life in Parkinson’s disease: a re-evaluation
A Schrag, N Quinn

566 Too much of a good thing: hedonistic homoeostatic dysregulation and other behavioural consequences of excessive dopamine replacement therapy in Parkinson’s disease
J D O’Sullivan

Editorial comments
568 Neurology in the time of COVID-19
H Manji, A S Carr, W J Brownlee, M P Lunn

571 Remember the null hypothesis?
C Randolph

Autonomic
572 New insights in post-traumatic headache with cluster headache phenotype: a cohort study
L Gramgeon, E O’Connor, C-K Chau, L Abijain, T M Pham Ngoc, M S Matharu

Cerebrovascular disease
580 Ten-year risks of recurrent stroke, disability, dementia and cost in relation to site of primary intracerebral haemorrhage: population-based study
L Li, R Luengo-Fernandez, S M Zauscher, N C Reddows, P Lavallée, L E Silver, W Kuker, P M Rothwell

Cognitive neurology
586 Clinical and neuropsychological profile of patients with dementia and chronic traumatic encephalopathy
C LoBue, J Schaffer, C M Callum, M E Peters, N Didehbani, J Hart, C L White

Migraine
593 Migraine and risk of stroke
L R Ote, T Kurth, S Gallat, D W Dodick

Neuro-inflammation
605 CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD

Neurodegeneration
612 Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>650</td>
<td>Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-Barré syndrome</td>
<td>H Koike, Y Fukami, R Nishi, Y Kawagashira, M Iijima, M Katsuno, G Sobue</td>
</tr>
<tr>
<td>660</td>
<td>Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)</td>
<td>H Butzkueven, L Kapros, H Wiendl, M Trojano, T Spelman, I Cheng, R Kasliwal, S Jaitly, N Campbell, P-R Ho, S Licata, On behalf of the Tysabri Observational Program (TOP) Investigators</td>
</tr>
<tr>
<td>669</td>
<td>Letters</td>
<td></td>
</tr>
</tbody>
</table>

**Neuropsychiatry**

**Neuromuscular**

**Multiple sclerosis**